Skip to main content
OpenTrials
Completed

NCT Number: NCT04752631

MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK

This is an open label multicentre trial, evaluating the utility of MRI-guided thrombolysis for stroke beyond time window by Tenecteplase (TNK-tPA). This exploratory study was to describe the feasibility and outcome of thrombolytic therapy with TNK-tPA in 4.5-24 hours after stroke guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Neurology, General Hospital of Northern Theater Command

Shenyang, 110016, China

About this study

In patients with acute stroke with an unknown time of onset, intravenous alteplase guided by a mismatch between diffusion-weighted imaging and FLAIR in the region of ischemia resulted in a significantly better functional outcome at 90 days. This trial will enroll acute ischemic stroke patients within 4.5 to 24 hours of onset. All the patients had an ischemic lesion that was visible on MRI diffusion-weighted imaging but no parenchymal hyperintensity on fluid-attenuated inversion recovery (FLAIR), which indicated that the stroke had a ischemic penumbra. Randomization will be 1:1 to TNK-tPA (experimental) or standard treatment (control), in compliance with guidelines for acute stroke. Clinical outcome was assessed by disability on the basis of the modified Rankin scale at 90 days follow-up, which will be performed by a blinded assessor.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient age 18-80 years;
  • The time from onset to treatment: 4.5-24 hours;
  • Acute Ischemic stroke confirmed by MRI;
  • NIHSS score :6-25, or NIHSS score≤ 5 but culprit vessel occlusion or severe stenosis ( ICA, MCA-M1/M2, ACA) on CTA/MRA;
  • Imaging requirements: (1) DWI infarct region: no more than 1/3 of middle cerebral artery territory or 1/2 of the anterior cerebral artery territory or 1/2 of the posterior cerebral artery territory; (2) DWI infarct volume <70 ml; (2) presence of DWI/Flair mismatch: DWI high signal and Flair visually normal;
  • the first onset of ischemic stroke or previous stroke with no obvious sequelae (mRS≤1);
  • Signed informed consent

Exclusion criteria

  • Planned endovascular treatment;
  • Serious neurological deficits before onset ( mRS ≥ 2);
  • Obvious head injuries or strokes within 3 months;
  • Subarachnoid hemorrhage;
  • History of intracranial hemorrhage;
  • Intracranial tumor, arteriovenous malformation or aneurysm;
  • Intracranial or spinal cord surgery within 3 months;
  • Arterial puncture at a noncompressible site within the previous seven days;
  • Active internal hemorrhage;
  • coagulation abnormalities: platelet count of <100000/mm3 ;
  • Aortic arch dissection;
  • Heparin therapy within 24 hours;
  • Infective endocarditis;
  • Oral warfarin is being taken and INR>1.6 or APTT abnormal;
  • oral anticoagulation therapy;
  • Systolic pressure ≥185 mmHg or diastolic pressure ≥110 mmHg;
  • Blood glucose < 50 mg/dl (2.7mmol/L);
  • Pregnancy;
  • Neurological deficit after epileptic seizures;
  • Major surgery within 1 month;
  • Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  • Myocardial infarction within 3 months;
  • allergy to study drugs;
  • Contradictory to MRI examination;
  • MRI image not qualified for evaluation;
  • Other serious illness;
  • Participating in other clinical trials within 3 months;
  • patients not suitable for this clinical studies considered by researcher.

Treatment and study plan

Tenecteplase

Drug

The participants received TNK-tPA thrombolytic therapy

Other names: TNK-tPA

Primary outcomes

  1. Proportion of modified Rankin Scale (mRS) 0-1

    Time frame: 90 Days

    the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome

Secondary outcomes

  1. Proportion of modified Rankin Scale (mRS) 0-2

    Time frame: 90 Days

    the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome

  2. Distribution of the modified Rankin Scale (mRS)

    Time frame: 90 Days

    the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome

  3. Changes in National Institute of Health stroke scale (NIHSS)

    Time frame: 24 hours and 1 week

    the minimum and maximum values of NIHSS are 42 and 0, respectively; higher NIHSS mean a worse outcome

  4. vascular events

    Time frame: 90 Days

    The incidence of stroke and other vascular events

  5. proportion of death

    Time frame: 14 days

    death due to any cause

Other outcomes

  1. Proportion of symptomatic intracranial hemorrhage (sICH)

    Time frame: 48 hours

    sICH was defined as 4 or more increase in NIHSS caused by hemorrhage

  2. Proportion of intraparenchymal hemorrhage (PH1 and PH2)

    Time frame: 48 hours

    Proportion of PH1 and PH2 within 48 hours after the treatment

  3. proportion of hemorrhagic transformation

    Time frame: 7 Days

    Intracranial hemorrhage assessed by MRI/CT

  4. any bleeding events

    Time frame: 7 Days

    proportion of any bleeding events

Sponsors and collaborators

Lead sponsor

General Hospital of Shenyang Military Region

Other

Registry information

Official study title

MRI-guided thrOmbolysis for Stroke bEyond Time Window by TNK (ROSE-TNK): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study

Acronym: ROSE-TNK

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Feb 12, 2021
Registry last updated
Aug 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.